Works matching IS 1007385X AND DT 2022 AND VI 29 AND IP 3
1
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 218, doi. 10.3872/j.issn.1007-385x.2022.03.008
- Article
2
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 225, doi. 10.3872/j.issn.1007-385x.2022.03.009
- 杨玥;
- 连斌;
- 王轩;
- 斯璐;
- 迟志宏;
- 盛锡楠;
- 毛丽丽;
- 崔传亮;
- 郭军
- Article
3
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 230, doi. 10.3872/j.issn.1007-385x.2022.03.010
- Article
4
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 258, doi. 10.3872/j.issn.1007-385x.2022.03.014
- Article
5
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 239, doi. 10.3872/j.issn.1007-385x.2022.03.011
- Article
6
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 251, doi. 10.3872/j.issn.1007-385x.2022.03.013
- Article
7
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 245, doi. 10.3872/j.issn.1007-385x.2022.03.012
- Article
8
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 209, doi. 10.3872/j.issn.1007-385x.2022.03.007
- Article
9
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 167, doi. 10.3872/j.issn.1007-385x.2022.03.001
- Article
10
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 195, doi. 10.3872/j.issn.1007-385x.2022.03.005
- Article
11
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 189, doi. 10.3872/j.issn.1007-385x.2022.03.004
- Article
12
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 181, doi. 10.3872/j.issn.1007-385x.2022.03.003
- 王田;
- 张征峥;
- 王晓峰;
- 张紫梦;
- 张雨晴;
- 马翠卿;
- 宋淑霞
- Article
13
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 175, doi. 10.3872/j.issn.1007-385x.2022.03.002
- Article
14
- Chinese Journal of Cancer Biotherapy, 2022, v. 29, n. 3, p. 202, doi. 10.3872/j.issn.1007-385x.2022.03.006
- Article